Background: Bladder cancers have different angiogenic pathways distinguishing not only papillary from solid tumours, but even papillary superfi cial from papillary invasive ones, thus representing selective targets for antiangiogenic drugs. Methods: The bacterial wall component tecogalan, inhibiting basic fi broblast growth factor (bFGF), the fumagillin derivative TNP-470, inhibiting vascular endothelial growth factor (VEGF), the distamycin A derivative PNU153429, and the tetracycline minocycline were administered to nude mice injected with the human bladder cancer cell lines 639V, causing bFGF-expressing papillary superfi cial tumours, or T24, causing VEGF-expressing papillary invasive tumours. Results: Tecogalan had no effect even on 639V tumour growth, where bFGF was unaffected. TNP-470 only had an effect on T24 tumours, delaying tumour appearance and growth and lowering VEGF; these effects were augmented by adding minocycline. PNU153429 had no effect on 639V tumours, and a slight effect on T24 tumours. Conclusion: TNP-470 may represent a selective drug for the treatment of VEGF expressing invasive papillary bladder tumours.
Antiangiogenic drugs for chemotherapy of bladder tumours
CALZA, Roberta;CORALLINI, Alfredo;
2005
Abstract
Background: Bladder cancers have different angiogenic pathways distinguishing not only papillary from solid tumours, but even papillary superfi cial from papillary invasive ones, thus representing selective targets for antiangiogenic drugs. Methods: The bacterial wall component tecogalan, inhibiting basic fi broblast growth factor (bFGF), the fumagillin derivative TNP-470, inhibiting vascular endothelial growth factor (VEGF), the distamycin A derivative PNU153429, and the tetracycline minocycline were administered to nude mice injected with the human bladder cancer cell lines 639V, causing bFGF-expressing papillary superfi cial tumours, or T24, causing VEGF-expressing papillary invasive tumours. Results: Tecogalan had no effect even on 639V tumour growth, where bFGF was unaffected. TNP-470 only had an effect on T24 tumours, delaying tumour appearance and growth and lowering VEGF; these effects were augmented by adding minocycline. PNU153429 had no effect on 639V tumours, and a slight effect on T24 tumours. Conclusion: TNP-470 may represent a selective drug for the treatment of VEGF expressing invasive papillary bladder tumours.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
